City of Hope announces three personnel changes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CITY of HOPE announced three recent hires.

Bart Roep joined City of Hope as chair of the Department of Diabetes Immunology within the Diabetes & Metabolism Research Institute.

Roep served as head of the Division of Autoimmunity and professor of medicine, diabetology, immunopathology and immune intervention therapy at Leiden University Medical Center in the Netherlands. He also served as director of the Netherlands’ National Diabetes Expert Center on Immunoprotection.

A recognized authority on multiple aspects of type 1 diabetes, including the potential for vaccine therapy to cure the disease, Roep has been honored with the JDRF Gerold & Kayla Grodsky Basic Research Scientist Award 2015 and the Minkowski Award for T1D Scientific Excellence 2004, the most prestigious national and European awards in diabetes.

Veronica Jones joined City of Hope as an assistant clinical professor in the department of surgery, specializing in breast surgery.

Jones was an assistant professor in the department of surgery at Emory University. At Baylor, Jones was honored as chief resident of the year. In 2014, she completed a breast surgical oncology fellowship at Emory University.

Daneng Li joined City of Hope as an assistant clinical professor in the department of medical oncology and therapeutics, specializing in geriatric oncology, and GI oncology

Li receive his medical doctorate from Weill Cornell Medical College in New York, before pursuing an internship and residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center. He recently completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City.

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login